Cancer prevention by bovine lactoferrin: from animal studies to human trial.

Abstract

Colorectal cancer (CRC) is one of the most frequently diagnosed cancers and, despite improved colonoscopic screening, CRC is a leading cause of death from cancer. Administration of bovine lactoferrin (bLF) suppresses carcinogenesis in the colon and other organs of test animals, and recently it was shown that ingestion of bLF inhibits the growth of adenomatous polyps in human patients. Here we review work which established bLF as an anti-carcinogenic agent in laboratory animals and the results of a clinical trial which demonstrated that bLF can reduce the risk of colon carcinogenesis in humans.

• Authors: Hiroyuki Tsuda, Takahiro Kozu, Gen Iinuma, Yasuo Ohashi, Yutaka Saito, Daizo Saito, Takayuki Akasu, David B Alexander, Mitsuru Futakuchi, Katsumi Fukamachi, Jiegou Xu, Tadao Kakizoe, Masaaki Iigo
• Journal: Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine (Biometals) Vol. 23 Issue 3 Pg. 399-409 (Jun 2010) ISSN: 1572-8773 [Electronic] Netherlands
• PMID: 20407806 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Anticarcinogenic Agents
• Lactoferrin

Topics

• Animals
• Anticarcinogenic Agents (pharmacology)
• Cattle
• Colorectal Neoplasms (pathology, prevention & control)
• Humans
• Lactoferrin (pharmacology)